in Health care
Shilpa Medicare Psoriatic arthritis drug Apremilast gets USFDA okay
Karnataka: Shilpa Medicare has recently announced that the Company has received final approval from the U.S Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Apremilast Tablets, 10 mg, 20 mg, and 30 mg. The medicine is indicated for the treatment of adult patients with active psoriatic arthritis. Psoriatic arthritis is a long-term inflammatory arthritis. It occurs in individuals […] More
